Dr. James J. Burke

Physiatry
10877 Conductor Blvd Ste 300, 
Sutter Creek, CA 
10877 Conductor Blvd Ste 300, 
Sutter Creek, CA 

Overview

James Burke is a Physiatrist practicing medicine in Sutter Creek, California.

His clinical expertise encompasses Non-Muscle Invasive Bladder Cancer.

He is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 22 clinical trials.

Specialties

Physiatry

Licenses

Rehabilitation Practitioner in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

10877 Conductor Blvd Ste 300, Sutter Creek, CA 95685

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

8 Total Publications

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
Journal: Molecular cancer therapeutics
Published: April 07, 2020
Similar Doctors
Expertise in
0
conditions
Expertise in
0
conditions
Referral may be required
590 Toyanza Drive, 
San Andreas, CA 
 (18.2 miles away)
209-754-6883
Languages Spoken:
English

Andrea Wright is a Physiatrist practicing medicine in San Andreas, California. Her clinical expertise encompasses Cerebral Palsy.

Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required
670 Placerville Dr, 
Placerville, CA 
 (20.8 miles away)
530-644-2412
Languages Spoken:
English

Heather Chapman is a Physiatrist practicing medicine in Placerville, California. Dr. Chapman is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Lenz Microphthalmia Syndrome.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required
Before you request
2380 East Bidwell St., 
Folsom, CA 
 (26.1 miles away)
916-306-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ramandeep Gurai is a Physiatrist practicing medicine in Folsom, California. Dr. Gurai is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Invertebral Disc Disease, Chronic Pain, Cervical Spondylosis, and Herniated Disk. Dr. Gurai is board certified in Physical Medicine And Rehabilitation - American Board Certified. Dr. Gurai is currently accepting new patients.

Expertise in
0
conditions
Expertise in
0
conditions
Referral may be required
Before you request
2380 East Bidwell St., 
Folsom, CA 
 (26.1 miles away)
916-306-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Kortebein is a Physiatrist practicing medicine in Folsom, California. His clinical expertise encompasses Muscle Atrophy. Dr. Kortebein is board certified in Physical Medicine And Rehabilitation - Board Certified. Dr. Kortebein is currently accepting new patients.

Expertise in
0
conditions
Expertise in
0
conditions
Referral may be required
Before you request

Donna A. Kalauokalani, MD

1750 Prairie City Rd, 130-248, 
Folsom, CA 
 (26.5 miles away)
916-467-4244
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Donna Kalauokalani is a Physiatrist practicing medicine in Folsom, California. Her clinical expertise encompasses Invertebral Disc Disease and Chronic Pain. Dr. Kalauokalani is board certified in Anesthesiology and Anesthesiology (Sub: Pain Medicine). Dr. Kalauokalani is currently accepting new patients.

Expertise in
1
conditions
Dr. Jennie Jet
Physiatry
Expertise in
1
conditions
Dr. Jennie Jet
Physiatry
Referral may be required

Mercy Hospice

3400 Data Dr, 
Rancho Cordova, CA 
 (30.6 miles away)
831-462-9955
Languages Spoken:
English
See accepted insurances

Jennie Jet is a Physiatrist practicing medicine in Rancho Cordova, California. Dr. Jet is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hemiplegia, Subdural Hematoma, Chronic Subdural Hematoma, X-Linked Myotubular Myopathy, and Gastrostomy.

Frequently Asked Questions about Dr. James J. Burke

How do I make an appointment with Dr. James J. Burke?

You can book an appointment with Dr. James J. Burke by calling their office at 209-223-6553. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James J. Burke a top-rated expert for Non-Muscle Invasive Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James J. Burke is classified as an Experienced expert for Non-Muscle Invasive Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James J. Burke specialize in?

While Dr. James J. Burke is a Physiatry, they have specific expertise in Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Physiatry.

Does Dr. James J. Burke participate in research or clinical trials?

Yes. Dr. James J. Burke has published 8 articles and abstracts on conditions like Non-Muscle Invasive Bladder Cancer. You can view a list of Dr. James J. Burke's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burke's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile